GNMSFOTCinactive

GENMAB A/S

Healthcare·Oncology·Phase 3·Copenhagen, Denmark
OncologyNephrology

GENMAB A/S (GNMSF): 23 pipeline candidates. Updated within the last hour.

9.3/10

BioSniper Score

2-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial HealthN/A

N/A

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth10.0

23 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for GENMAB A/Sacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$15.3B

Cash

—

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (23 candidates)

DrugPhase
5-fuPhase 1/Phase 2
bendamustinePhase 3
cc-99282Phase 2
daratumumabPhase 1/Phase 2
gen1053Phase 1/Phase 2
gen1055Phase 1/Phase 2
gen1056Phase 1
gen1057Phase 1/Phase 2
gen1078Phase 1/Phase 2
gen1079Phase 1/Phase 2

Showing 10 of 23 candidates. Sign up for full pipeline.

·CEO: Dr. Jan G.J. van de Winkel Ph.D.

Frequently asked questions

How many drug candidates are in GENMAB A/S's pipeline?

GENMAB A/S (GNMSF) has 23 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is GENMAB A/S's lead drug candidate?

GENMAB A/S's most advanced tracked candidate is 5-fu (Phase 1/Phase 2) for Malignant Solid Tumor.

What is GENMAB A/S's market capitalization?

GENMAB A/S's market capitalization is approximately $15.3B.

Who is the CEO of GENMAB A/S?

Dr. Jan G.J. van de Winkel Ph.D. is the chief executive officer of GENMAB A/S (GNMSF).

Get the full picture on GENMAB A/S

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar